Related Experiment Videos
Targeted therapies for gynecologic malignancies.
Johnny Hyde1, D Scott McMeekin
1University of Oklahoma- HSC, PO Box 26901, Oklahoma City, OK 73190, USA.
Current Treatment Options in Oncology
|February 19, 2005
Summary
Targeted therapies show promise for gynecologic cancers, but are not yet ready for widespread use. Further research is needed to determine efficacy and optimal study designs for these novel treatments.
Area of Science:
- Oncology
- Gynecologic Oncology
- Pharmacology
Background:
- Targeted therapies offer significant potential for treating gynecologic malignancies.
- Current use of targeted therapies is limited, necessitating further investigation before clinical recommendation.
Purpose of the Study:
- To review strategies for developing targeted agents in gynecologic cancers.
- To examine available targeted therapies and their potential roles.
- To discuss challenges in clinical trial design and efficacy assessment.
Main Methods:
- Literature review of targeted therapy development strategies.
- Analysis of existing targeted therapies for gynecologic malignancies.
- Discussion of clinical trial methodologies and endpoints.
Main Results:
- Tumor-specific targets exist, but target expression does not always predict patient benefit.
- Defining efficacy endpoints (response vs. cytostatic effects) is crucial.
- Combination therapies require demonstration of additive or synergistic effects.
Conclusions:
- Targeted therapies are not yet established treatments for gynecologic cancers outside clinical trials.
- Significant research is required to optimize the study and application of targeted agents.
- Future strategies may involve combination therapies and refined clinical trial designs.